USA flag logo/image

An Official Website of the United States Government

A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
60460 		Program Year/Program:
2002 / STTR
Agency Tracking Number:
AI046852 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
ADENOSINE THERAPEUTICS, LLC
310 FOURTH STREET NE SUITE 201 CHARLOTTESVILLE, VA 22902
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION
Agency: HHS
Contract: 2R42AI046852-02
Award Amount: $0.00
 

Abstract:

epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of Iipopolysaccaride-and live E. coli-induced septic shock. Screening 30 newly-synthesized A2AAR agonists showed that the prototype, ATL146e, remained the most potent, selective and least likely to have toxic metabolites. In phase II we propose additional studies on ATL146e aiming at an IND application. Aim 1 will characterize the acute, single-dose toxicology, pharmacokinetics and metabolism of ATL146e. Aim 2 will develop methods for the scale-up of the synthesis of 2-iodoNECA, the key intermediate in the synthesis of ATL146e, and will characterize its stability, solubility and formulation. Aim 3 will optimize treatment regimens with ATL146e in a mouse model of E. coli peritonitis and bacteremia. Aim 4 examines the effect of treatment with ATL146e on end points other than mortality, namely dysfunction of liver, kidney and lung, as well as on cytokine responses that could be useful in patient monitoring.

Principal Investigator:

Robert D. Thompson
4349519484
RDT@ADENRX.COM

Business Contact:

Mary Nadler
4342209400
MNADLER@ADENOSINETHERAPEUTICS.COM
Small Business Information at Submission:

ADENOSINE THERAPEUTICS, LLC
ADENOSINE THERAPEUTICS, LLC 300 PRESTON AVE, 5TH FL CHARLOTTESVILLE, VA 22902

EIN/Tax ID: 541932209
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF VIRGINIA
UVA
CHARLOTTSVILLE, VA 24615
RI Type: Nonprofit college or university